News

Skye confirms phase 2 data on nimacimab for obesity expected later this year
Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...
Futurism1h
Something Comically Bad Just Happened to the Inventor of Ozempic
Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...
Investor's Business Daily on MSN1h
How IBD 50's Hims & Hers Is Shaking Up The Weight-Loss Brawl
In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.
Ozempic, a patent challenge, and the $25 billion race for India’s weight-loss drug market
Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...
The Manila Times12h
Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024
Landmark investments, portfolio progress, and expanded presence position ...
FDA’s removal of Ozempic, Wegovy from drug shortage list upheld
A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...
U.S. judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...
Novo Nordisk stock rating reiterated at Buy by TD Cowen
TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...